In the pivotal 8-week single arm, open-label adjunctive-to-insulin renal mechanistic pilot trial of empagliflozin in 40 subjects with T1DM, improvements in HbA1C, hypoglycemic risk, and weight loss were observed.[10, 16, 17] To further characterize the glycemic effects of empagliflozin, we explored diurnal glycemic patterns from interstitial fluid enzyme-based CGM using analysis by ambulatory glucose profiles (AGP).[18] Additionally, we evaluated these diurnal patterns stratified according to insulin pump and multiple daily injection (MDI) subgroups. This evidence concerns the gene INS and type 1 diabetes mellitus.